Navigation Links
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Date:8/11/2009

enosumab twice-yearly experienced a 68 percent reduction in the risk of suffering a vertebral (spine) fracture compared to those receiving placebo as well as a 40 percent reduction in the risk of suffering a hip fracture and a 20 percent reduction in the risk of suffering a nonvertebral fracture. Over the three years of this multi-center, randomized, double-blind, placebo-controlled study, women treated with denosumab experienced significant increases in BMD (8.8 percent at the lumbar spine and 6.4 percent at the total hip).(1)

"These results suggest that denosumab offers a new approach to prevention of fractures in women with postmenopausal osteoporosis," said Steven Cummings M.D., lead investigator, study author, and director of the San Francisco Coordinating Center of the California Pacific Medical Center Research Institute. "It reduces the risk of all major types of fractures and, because it is given as an injection twice a year, it also has the potential to help compliance to treatment."

Fracture is one of the most common health events suffered by postmenopausal women with osteoporosis.(3) Globally, one woman in three over 50 years of age will experience a fracture in her lifetime.(3) A woman who has broken a bone as a result of osteoporosis has more than an eight- out-of-ten chance of breaking another bone.(4) Half of women who break a hip, a life changing event, will permanently need assistance to walk.(5)

The overall incidence and type of side effects with denosumab were similar to placebo in the FREEDOM study. Rates of adverse events (AEs) were similar in both groups (93 percent). Rates of serious AEs were 25.8 percent for denosumab and 25.1 percent for placebo. The most common AEs across both treatment arms were arthralgia, back pain, hypertension and nasopharyngitis. There were no reported cases of osteonecrosis of the jaw among patients taking denosumab. Serious adverse events of skin infections,
'/>"/>

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
(Date:12/24/2014)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Jennifer Hagerman , Pharm.D., AE-C, senior director of ... the president of the Michigan Pharmacists Association on Jan. ... Feb. 28, 2015, at the MPA Annual Convention and ... in Detroit, Michigan . Hagerman will ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... showed patients taking prasugrel had lower ... stroke or cardiovascular death after first event than ... A new,pre-specified analysis of the landmark Phase III ... acute coronary syndromes,(ACS) managed with an artery-opening procedure known ...
... 21 Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today ... in the United Kingdom has authorized a Phase 1,study ... lead product candidate for the treatment of gout., ... 1 study of,RDEA594, within six months from designation as ...
Cached Medicine Technology:Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 2Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 3Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 4Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 5Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 4
(Date:12/26/2014)... India Network Foundation, a non-profit US ... announced today a new version of “ EasySelect ”, ... right plan for their visiting parents. The technology tool ... selection process when choosing an insurance plan by showing ... a few clicks. Many elderly Asian Indian parents often ...
(Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and ... Today, the company announces big discounts on its ... colors. , BambooFlooringChina.com is the world’s leader in bamboo ... valid until Jan. 20, 2015. , The bamboo mats ... a natural thread. All the bamboo strips for the ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Don't Let Burns Mar Your Holidays 2
... At the 14th annual retrovirus conference in Los Angeles, it ... the United States//. According to Harold Jaffe, a professor of ... no signs of decreasing. ,He also ... fresh infection of HIV cases. Jaffe emphasized on the scientific ...
... to a latest study, the ages at which teenagers and ... a significant impact on their delinquent behavior//. The level of ... earlier than their peer group and vice versa. ... of Youth and Adolescence. Stacy Armour the co-author of this ...
... Inc. today announced the first patient implant in a ... near the spinal cord will control// chronic chest pain ... is the first person to receive this investigational device, ... approximately 1.3 million Americans who suffer from chronic angina, ...
... of Technology researchers have engineered a way to deliver ... as carriers. The breakthrough could lead to low fat ... in fat-containing foods, and could be used to enrich ... ,The team, led by Dr. Yoav ...
... be in gold nanoparticles - tiny pieces of gold so ... potential of gold nanoparticles has been hindered by the difficulty ... be injected into a patient. New research at the University ... used to overcome this problem, creating a new type of ...
... the world's leading pharmaceutical companies, issued a press release ... metastatic prostate cancer. ,A Phase III ... to Novantrone (mitoxantrone) plus prednisone. The study included a ... spread of disease after hormonal therapy., ,The results ...
Cached Medicine News:Health News:Spinal Cord Stimulation Pilot Study for Chronic Angina 2Health News:Natural Milk Protein Could Lead to Super Nutritious Foods 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 3
These retractors are packaged singly ready for sterilization at your facility....
These retractors are packaged singly ready for sterilization at your facility....
HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin....
... aureus and methicillin resistant coagulase-negative staphylococci in ... MRSA Latex Kit for PBP2/ detects Penicillin ... Staphylococcus aureus and coagulase-negative staphylococci. PBP2/ is ... and is present in the membranes of ...
Medicine Products: